Integrated Filing — IndAS



General information about company

Scrip Code 540937
NSE Symbol MEDICO
MSEI Symbol NOTLISTED
ISIN INE630Y01024
Name of company MEDICO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-02-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment manufacturer and exporter of pharmaceutical formulations
Start date and time of board meeting 12-02-2026   17:00:00
End date and time of board meeting 12-02-2026   17:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,868.29 14,956.96
Other income 67.68 305.97
Total income 5,935.97 15,262.93
2 Expenses
(a) Cost of materials consumed 3,618.44 10,824.28
(b) Purchases of stock-in-trade 221.47 395.73
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 570.91 (30.88)
(d) Employee benefit expense 212.92 564.27
(e) Finance costs 38.63 90.24
(f) Depreciation, depletion and amortisation expense 79.02 229.28
(f) Other Expenses
1 Manufacturing Expenses 398.79 1,191.44
2 Selling and Distribustion Expenses 231.76 583.10
3 Other Business Administrative Expenses 180.79 441.43
Total other expenses 811.34 2,215.97
Total expenses 5,552.73 14,288.89
3 Total profit before exceptional items and tax 383.24 974.04
4 Exceptional items 0.00 0.00
5 Total profit before tax 383.24 974.04
6 Tax expense
7 Current tax 86.00 217.00
8 Deferred tax 10.00 31.18
9 Total tax expenses 96.00 248.18
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 287.24 725.86
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 287.24 725.86
17 Other comprehensive income net of taxes 0.12 0.36
18 Total Comprehensive Income for the period 287.36 726.22
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,659.68 1,659.68
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.35 0.87
Diluted earnings (loss) per share from continuing operations 0.35 0.87
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.35 0.87
Diluted earnings (loss) per share from continuing and discontinued operations 0.35 0.87
24 Debt equity ratio 0 0
25 Debt service coverage ratio 18.6400 20.5300
26 Interest service coverage ratio 18.6400 20.5300
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on February 12, 2026 and subsequently approved by the Board of Directors at its meeting held on February 12, 2026. The review report has been filed with stock exchange and is available on the Company’s website. 2. The figures for the quarter ended on 31st December 2025 are balancing figures between the reviewed figures for the quarter ended 30th September 2025 and reviewed year to date figures upto nine months ended 31st December 2025. 3. The standalone financial results for the quarter ended on 31st December, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. 4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. 5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: PARTICULARS QE 31.12.2025 QE 30.09.2025 Amount (Rs. In Lakh) Amount (Rs. In Lakh) 1)Sales of products within India 689.73 542.92 2)Sales of products Outside India 5156.033 4675.40 Sub- Total 5845.77 5218.32 6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. 7. The company does not have any subsidiary/associate/joint venture company as on 31st December 2025. 8. The result for the quarter ended December 31, 2025 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) For and on behalf of the board, For Medico Remedies Limited Rishit Mehta Harshit Mehta Whole Time Director Managing Director DIN: 07121224 DIN:05144280 Place: Mumbai Place: Mumbai Date: February 12, 2026 Date: February 12, 2026



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plan 0.16 0.48
2 Income tax related to items no (i) above (0.04) (0.12)
Total Amount of items that will not be reclassified to profit and loss 0.12 0.36
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.12 0.36